Clinical Trials Logo

Clinical Trial Summary

This is a prospective trial for a computation-based efficacy prediction method for anticancer target therapies. The original computational algorithm utilizes individual transcriptome data of a cancer sample and assesses changes at the level of gene expression and intracellular signaling pathways. By applying the database of known molecular targets of anticancer target drugs it allows to rank potential efficacies of target drugs.

Clinical Trial Description

Original computational algorithm Oncobox was developed to determine molecular features of individual tumors. It represents the solution for a personalized selection of target anticancer therapies. The method is based on the analysis of gene expression profile of a cancer sample in comparison with the corresponding normal tissue biosamples in order to select the most effective molecular targets for their inhibition and, accordingly, to identify more effective target drugs for cancer treatment. Histological material obtained from cancer patients during surgery or core-needle biopsy as part of standard treatment will be used for the analysis. Total RNA extracted from the tumor material will be subjected to next-generation sequencing (NGS). By comparing transcriptome profile of the tumor sample with the profiles of the corresponding normal tissue samples the rate of molecular pathways activation/deactivation will be calculated, as well as the case-to-normal ratios for the individual gene products - molecular targets of drugs. Based on these data, each target drug will be assigned with a score reflecting its potential efficacy for each individual tumor treatment. A drug with the score value above 0.1 will be considered potentially effective, a drug with the score value equal to or below 0.1 - as potentially ineffective. Following Oncobox test, 130 target anticancer drugs will be rated according to their predicted effectiveness (see the list of eligible target drugs below). This information will be fully available to a patient and his/her doctor. The doctor will prescribe treatment according to his/her consideration, e.g. based on the standards of care and the patient's life indications. After the appointment of therapy, the patients will be divided naturally into the following three observation groups. The first group will be formed from patients receiving target drugs with the score value above 0,1 as monotherapy or in combination. The second group - patients receiving only non-target drugs or target drugs with the score value equal to or below 0,1 as monotherapy or in combination. Third group will be formed by patients receiving palliative care. Within this study, these three groups will be compared by response to the therapy according to the results of instrumental studies, by time to progression and by time to progression compared to the previous line of therapy (if any). Additionally, overall survival will be measured in all three groups.

Eligible target drugs:

1. Abemaciclib (LY2835219)

2. Afatinib

3. Aflibercept

4. Alectinib

5. Alemtuzumab

6. Alitretinoin

7. Anastrozole

8. Apalutamide, ARN-509

9. Arsenic trioxide

10. Atezolizumab

11. Avelumab

12. Axitinib

13. Belinostat

14. Bevacizumab

15. Bexarotene

16. Bicalutamide

17. Binimetinib (MEK162)

18. Blinatumomab

19. Bortezomib

20. Bosutinib

21. Brentuximab vedotin

22. Brigatinib

23. Cabazitaxel

24. Cabozantinib

25. Carfilzomib

26. Ceritinib (Zykadia, LDK378)

27. Cetuximab

28. Cobimetinib

29. Crizotinib

30. CYT387 (Momelotinib)

31. Dabrafenib

32. Daratumumab

33. Dasatinib

34. Degarelix

35. Denileukin diftitox (Ontac)

36. Denosumab

37. Docetaxel

38. Dovitinib

39. Durvalumab

40. Elotuzumab

41. Encorafenib

42. Enzalutamide

43. Erlotinib

44. Estramustine

45. Everolimus

46. Exemestane

47. Flavopiridol (Alvociclib)

48. Foretinib

49. Fulvestrant

50. Ganetespib (STA-9090)

51. Gefitinib

52. Goserelin

53. Homoharringtonine (Omacetaxine mepesuccinate)

54. Ibritumomab tiuxetan

55. Ibrutinib

56. Idelalisib

57. Imatinib

58. Inotuzumab ozogamicin

59. Ipilimumab

60. Ixabepilone

61. Ixazomib (MLN9708)

62. Lapatinib

63. Lenalidomide

64. Lenvatinib

65. Letrozole

66. Leuprolide

67. Lomustine

68. Masitinib

69. Medroxyprogesterone acetate (MPA)

70. Megestrol

71. Methyltestosterone

72. Midostaurin

73. Mogamulizumab

74. Moxetumomab pasudotox

75. Necitumumab

76. Nilotinib

77. Nilutamide

78. Nimotuzumab

79. Nintedanib (BIBF 1120)

80. Niraparib

81. Nivolumab (BMS-936558)

82. Obinutuzumab

83. Ofatumumab

84. Olaparib

85. Olaratumab

86. Osimertinib

87. Paclitaxel

88. Palbociclib

89. Panitumumab

90. Panobinostat

91. Pazopanib

92. Pembrolizumab

93. Perifosine

94. Pertuzumab

95. Pomalidomide

96. Ponatinib

97. Ramucirumab (Cyramza)

98. Regorafenib

99. Ribociclib

100. Rigosertib

101. Rituximab

102. Romidepsin

103. Rucaparib

104. Ruxolitinib

105. Selumetinib

106. Siltuximab

107. Sonidegib (LDE225)

108. Sorafenib

109. Sunitinib

110. Tamoxifen

111. Tecemotide (Emepepimut-S, L-BLP25)

112. Temozolomide

113. Temsirolimus

114. Thalidomide

115. Tivantinib

116. Tivozanib

117. Toremifene

118. Trametinib (Mekinst)

119. Trastuzumab

120. Trebananib

121. Vandetanib

122. Veliparib

123. Vemurafenib

124. Venetoclax

125. Vinblastine

126. Vincristine

127. Vindesine

128. Vinorelbine

129. Vismodegib

130. Vorinostat ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03724097
Study type Observational
Source OmicsWay Corp.
Contact Anton A Buzdin, Ph.D., D.Sc
Phone +18883822725
Status Recruiting
Start date October 17, 2017
Completion date November 1, 2022

See also
  Status Clinical Trial Phase
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Active, not recruiting NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Completed NCT01077414 - Phenomenological Study of Psycho-Socio-Spiritual Healing in the Context of Chronic or Life-Threatening Illness
Completed NCT01340846 - A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors Phase 1
Recruiting NCT02565004 - Clinical and Laboratory Analysis of Familial Cancer
Active, not recruiting NCT02502396 - Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center N/A
Not yet recruiting NCT03662061 - Assessment of a Multidisciplinary Team Meeting (RCP) in Geriatric Oncology
Completed NCT03272880 - Utilizing the Arts to Improve Health, Resilience, and Well-Being Among Cancer Patients and Their Caregivers N/A
Active, not recruiting NCT00587886 - Estrogen, Diet, Genetics and Endometrial Cancer
Recruiting NCT03548077 - POWERPLAY: Promoting Men's Health at Work N/A
Completed NCT03503838 - A Pilot Study of Online Yoga for MPN Patients N/A
Completed NCT00984035 - Investigation of Cisplatin-Related Kidney Toxicity
Completed NCT01447186 - Adaptation of the American Cancer Society (ACS) Early Detection of Prostate Cancer Patient Decision Aid for Spanish Speaking Men N/A
Not yet recruiting NCT03257969 - Impact of the DROP Program on the DRP (Drug Related Problems) Related to Oral Anticancer Drugs in Ambulatory Patients With Risk Factors N/A
Recruiting NCT02869802 - Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis